Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to ...

Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs ... address key pathways in metabolic aging. DOWNLOAD ...

The discovery of a gut-to-brain regulation pathway in flies calls for additional consideration on how certain medications, especially GLP-1 agonists, can be used to treat obesity and diabetes in ...

Biologists at Brown University have discovered how a neuropeptide hormone made in the gut of flies can control their lifespan ...

It also describes the various GLP-1s on the market and the differences between them. Glucagon-like peptide (GLP-1) is a type of hormone known as an incretin that's lower than normal in people with ...

The journey to a college degree contains major detours for more students than it may initially appear. Long heralded as the most critical pathway to economic mobility and personal fulfillment, higher ...

SUMO proteins intervene in the progression of DN by modulating various signaling cascades, such as Nrf2-mediated oxidative stress, NF-κB, TGF-β, and MAPK pathways. Recent advancements indicate that ...

Recently, these incretin drugs also became very popular as a treatment of obesity (combined with life style improvements). Both liraglutide (brand names Saxenda® and Victoza®) and semaglutide (brand ...

What’s sparking considerable interest is that it’s additive to incretin-based therapies, which are already effective for weight loss. The weight loss is so significant, it rivals some ...